Managed Care Update - Expert Recommendations and Developments in AML Management
Jointly provided by
Impact Education, LLC    
This activity is supported by an independent educational grant from Jazz Pharmaceuticals, Inc.

You Are Invited to a LIVE Free CME/CNE/CPE Webcast:
Managed Care Update - Expert Recommendations and Developments in AML Management

Live Webcast Date

January 30, 2020 | 12:30pm to 2pm ET - Click Here to Register for This Date
February 20, 2020 | 1:30pm to 3:00pm ET - Click Here to Register for This Date

  • Describe the clinical and economic burden of AML
  • Differentiate emerging agents from currently available treatment regimens
  • Quantify the impact that emerging therapies for AML may have
Amir T. Fathi, MD
Director of Leukemia, Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine, Harvard Medical School
Christopher A. Fausel, PharmD, MHA, BCOP
Clinical Manager, Oncology Pharmacy
Indiana University Simon Cancer Center
John Fox, MD, MHA
Vice President, Associate Chief Medical Officer, Medical Affairs
Priority Health
  • Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors
  • Pharmacy directors, specialty pharmacists, quality directors, care managers, registered nurses, and other managed care and payer organization professionals

Acute myeloid leukemia (AML) represents a key hematologic malignancy in managed care, with a relatively high prevalence among all leukemia types and significant associated morbidity and mortality. An estimated 21,450 new cases of AML are expected to be diagnosed in 2019, representing approximately one-third of all new cases of leukemia. In addition, the rate of new AML cases has been rising on average 3.7% each year over the last 10 years: the highest incidence rate among all forms of leukemia. This educational activity is improve managed care professionals' knowledge and competence related to the management of AML and the emergence of newer treatments.


After completing the activity, participants should be better able to:
  • Describe the clinical burden of AML in terms of prevalence, relative survival, and mortality
  • Characterize the economic burden of AML in terms of drug utilization, adverse event management, and hospitalizations
  • Differentiate emerging agents from currently available treatment regimens for AML as they pertain to efficacy, safety, and mechanism of action
  • Quantify the impact that emerging therapies for AML may have on health care resource utilization
  • Cite the adverse effect of cost-sharing and exclusive formulary strategies on patient access and therapeutic persistence in AML
  • Employ interventions such as clinical pathways and site of care initiatives for optimal cost management and improved outcomes in AML
Opening Comments/Overview
John Fox, MD, MHA
Clinical Scenarios in AML and the Appropriate Use of Emerging Pharmacologic Treatments
Amir T. Fathi, MD
Considerations in Therapeutic Positioning and Benefit Design for Emerging AML Therapies
John Fox, MD, MHA
Care Coordination and Disease Management Strategies for Optimal AML Outcomes
Christopher A. Fausel, PharmD, MHA, BCOP
Faculty Idea Exchange
Audience Question and Answer Session

Key Takeaways and Closing Comments
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008162-9999-20-985-L01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

If you have any questions, please call (215) 619-8812 or email